Analysis of early neonatal case fatality rate among newborns with congenital hydrocephalus, a 2000-2014 multi-country registry-based study.

ETOPFA birth defects case fatality rate congenital hydrocephalus early neonatal deaths population surveillance prevalence trends

Journal

Birth defects research
ISSN: 2472-1727
Titre abrégé: Birth Defects Res
Pays: United States
ID NLM: 101701004

Informations de publication

Date de publication:
15 07 2022
Historique:
revised: 05 04 2022
received: 09 02 2022
accepted: 29 04 2022
pubmed: 29 5 2022
medline: 19 7 2022
entrez: 28 5 2022
Statut: ppublish

Résumé

Congenital hydrocephalus (CH) comprises a heterogeneous group of birth anomalies with a wide-ranging prevalence across geographic regions and registry type. The aim of the present study was to analyze the early neonatal case fatality rate (CFR) and total birth prevalence of newborns diagnosed with CH. Data were provided by 25 registries from four continents participating in the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) on births ascertained between 2000 and 2014. Two CH rates were calculated using a Poisson distribution: early neonatal CFR (death within 7 days) per 100 liveborn CH cases (CFR) and total birth prevalence rate (BPR) per 10,000 births (including live births and stillbirths) (BPR). Heterogeneity between registries was calculated using a meta-analysis approach with random effects. Temporal trends in CFR and BPR within registries were evaluated through Poisson regression modeling. A total of 13,112 CH cases among 19,293,280 total births were analyzed. The early neonatal CFR was 5.9 per 100 liveborn cases, 95% confidence interval (CI): 5.4-6.8. The CFR among syndromic cases was 2.7 times (95% CI: 2.2-3.3) higher than among non-syndromic cases (10.4% [95% CI: 9.3-11.7] and 4.4% [95% CI: 3.7-5.2], respectively). The total BPR was 6.8 per 10,000 births (95% CI: 6.7-6.9). Stratified by elective termination of pregnancy for fetal anomalies (ETOPFA), region and system, higher CFR were observed alongside higher BPR rates. The early neonatal CFR and total BPR did not show temporal variation, with the exception of a CFR decrease in one registry. Findings of early neonatal CFR and total BPR were highly heterogeneous among registries participating in ICBDSR. Most registries with higher CFR also had higher BPR. Differences were attributable to type of registry (hospital-based vs. population-based), ETOPFA (allowed yes or no) and geographical regions. These findings contribute to the understanding of regional differences of CH occurrence and early neonatal deaths.

Sections du résumé

BACKGROUND
Congenital hydrocephalus (CH) comprises a heterogeneous group of birth anomalies with a wide-ranging prevalence across geographic regions and registry type. The aim of the present study was to analyze the early neonatal case fatality rate (CFR) and total birth prevalence of newborns diagnosed with CH.
METHODS
Data were provided by 25 registries from four continents participating in the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) on births ascertained between 2000 and 2014. Two CH rates were calculated using a Poisson distribution: early neonatal CFR (death within 7 days) per 100 liveborn CH cases (CFR) and total birth prevalence rate (BPR) per 10,000 births (including live births and stillbirths) (BPR). Heterogeneity between registries was calculated using a meta-analysis approach with random effects. Temporal trends in CFR and BPR within registries were evaluated through Poisson regression modeling.
RESULTS
A total of 13,112 CH cases among 19,293,280 total births were analyzed. The early neonatal CFR was 5.9 per 100 liveborn cases, 95% confidence interval (CI): 5.4-6.8. The CFR among syndromic cases was 2.7 times (95% CI: 2.2-3.3) higher than among non-syndromic cases (10.4% [95% CI: 9.3-11.7] and 4.4% [95% CI: 3.7-5.2], respectively). The total BPR was 6.8 per 10,000 births (95% CI: 6.7-6.9). Stratified by elective termination of pregnancy for fetal anomalies (ETOPFA), region and system, higher CFR were observed alongside higher BPR rates. The early neonatal CFR and total BPR did not show temporal variation, with the exception of a CFR decrease in one registry.
CONCLUSIONS
Findings of early neonatal CFR and total BPR were highly heterogeneous among registries participating in ICBDSR. Most registries with higher CFR also had higher BPR. Differences were attributable to type of registry (hospital-based vs. population-based), ETOPFA (allowed yes or no) and geographical regions. These findings contribute to the understanding of regional differences of CH occurrence and early neonatal deaths.

Identifiants

pubmed: 35633200
doi: 10.1002/bdr2.2045
pmc: PMC9288486
mid: NIHMS1812338
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

631-644

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

© 2022 Wiley Periodicals LLC.

Références

Paediatr Perinat Epidemiol. 2019 Nov;33(6):436-448
pubmed: 31637749
Rev Panam Salud Publica. 2019 Feb 14;43:e2
pubmed: 31093226
Paediatr Perinat Epidemiol. 2001 Jul;15(3):315-6
pubmed: 11489162
Neurotoxicology. 2017 Jul;61:33-45
pubmed: 27000516
Pediatr Neurol. 2011 Aug;45(2):67-71
pubmed: 21763944
Ann Hum Genet. 1971 Feb;34(3):295-305
pubmed: 4926846
Ann Neurol. 2017 Jun;81(6):890-897
pubmed: 28556411
Birth Defects Res. 2020 Dec;112(20):1787-1801
pubmed: 33067932
J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1253-9
pubmed: 24667207
Ultrasound Obstet Gynecol. 2017 Apr;49(4):450-459
pubmed: 27091707
Glob J Health Sci. 2014 Apr 27;6(5):1-8
pubmed: 25168985
Am J Med Genet. 2001 Jul 22;102(1):36-43
pubmed: 11471170
JAMA. 2002 Mar 27;287(12):1561-7
pubmed: 11911759
Ann Epidemiol. 2021 Apr;56:61-69.e3
pubmed: 33253899
Eur J Paediatr Neurol. 2010 Mar;14(2):150-5
pubmed: 19410489
PLoS One. 2018 Oct 1;13(10):e0204926
pubmed: 30273390
J Neurosurg. 2018 Apr 1;:1-15
pubmed: 29701543
J Matern Fetal Neonatal Med. 2019 Nov;32(21):3666-3674
pubmed: 29739244
J Med Ethics. 2006 Nov;32(11):652-7
pubmed: 17074823
Ann Hum Biol. 2004 Mar-Apr;31(2):263-9
pubmed: 15204368
Metab Brain Dis. 2018 Jun;33(3):837-842
pubmed: 29388147
Paediatr Perinat Epidemiol. 2020 Mar;34(2):122-129
pubmed: 32101337
J Neurosurg. 2005 Aug;103(2 Suppl):111; discussion 111-2
pubmed: 16370274
Oncotarget. 2018 Jan 13;9(18):14472-14480
pubmed: 29581857
Neurosurg Focus. 2016 Nov;41(5):E3
pubmed: 27798989
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Juan Antonio Gili (JA)

ECLAMC, Centro de Educación Médica e Investigaciones Clínicas (CEMIC-CONICET), Buenos Aires, Argentina.
Instituto Académico Pedagógico de Ciencias Humanas, Universidad Nacional de Villa María, Córdoba, Argentina.

Jorge Santiago López-Camelo (JS)

ECLAMC, Centro de Educación Médica e Investigaciones Clínicas (CEMIC-CONICET), Buenos Aires, Argentina.

Wendy N Nembhard (WN)

Department of Epidemiology, Arkansas Center for Birth Defects Research and Prevention and Arkansas Reproductive Health Monitoring System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Marian Bakker (M)

Department of Genetics, University of Groningen, University Medical Center Groningen, EUROCAT Northern Netherlands, Groningen, The Netherlands.

Hermien E K de Walle (HEK)

Department of Genetics, University of Groningen, University Medical Center Groningen, EUROCAT Northern Netherlands, Groningen, The Netherlands.

Erin B Stallings (EB)

Metro Atlanta Congenital Defects Program (MACDP), Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, Georgia, USA.

Vijaya Kancherla (V)

Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
As listed in http://www.fundacion1000.es/Estructura-del-ECEMC for year 2021, Spain.

Paolo Contiero (P)

Lombardy Congenital Anomalies Registry, Cancer Registry Unit, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.

Saeed Dastgiri (S)

Health Services Management Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.

Marcia L Feldkamp (ML)

Division of Medical Genetics, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Amy Nance (A)

Utah Birth Defect Network, Bureau of Children with Special Health Care Needs, Division of Family Health and Preparedness, Utah Department of Health, Salt Lake City, Utah, USA.

Miriam Gatt (M)

Malta Congenital Anomalies Registry, Directorate for Health Information and Research, Tal-Pietà, Malta.

Laura Martínez (L)

Genetics Department, Hospital Universitario Dr. José E. González, Universidad Autonóma de Nuevo León, San Nicolás de los Garza, Mexico.

María Aurora Canessa (MA)

Regional Register Congenital Malformation Maule Health Service (RRMC-SSM), Maule, Chile.

Boris Groisman (B)

National Network of Congenital Anomalies of Argentina (RENAC), National Center of Medical Genetics, National Administration of Laboratories and Health Institutes (ANLIS), National Ministry of Health and Social Development, Buenos Aires, Argentina.

Paula Hurtado-Villa (P)

Department of Basic Sciences of Health, School of Health, Pontificia Universidad Javeriana, Cali, Colombia.

Karin Källén (K)

National Board of Health and Welfare, Stockholm, Sweden.

Danielle Landau (D)

Department of Neonatology, Soroka Medical Center, Beer-Sheva, Israel.

Nathalie Lelong (N)

Université de Paris, CRESS Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), INSERM, INRA, Paris, France.

Margery Morgan (M)

CARIS, The Congenital Anomaly Register for Wales, Singleton Hospital, Swansea, Wales, UK.

Jazmín Arteaga-Vázquez (J)

Department of Genetics, RYVEMCE, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico.

Anna Pierini (A)

Institute of Clinical Physiology, National Research Council and Fondazione Toscana Gabriele Monasterio, Tuscany Registry of Congenital Defects, Pisa, Italy.

Anke Rissmann (A)

Medical Faculty, Malformation Monitoring Centre Saxony-Anhalt, Otto-von-Guericke University, Magdeburg, Germany.

Antonin Sipek (A)

Department of Medical Genetics, Thomayer University Hospital, Prague, Czech Republic.

Elena Szabova (E)

Slovak Teratologic Information Centre (FPH), Slovak Medical University, Bratislava, Slovak Republic.

Wladimir Wertelecki (W)

Omni-Net for Children International Charitable Fund, Rivne, Ukraine.

Ignacio Zarante (I)

Human Genetics Institute, Pontificia Universidad Javeriana, Bogotá, Colombia.

Mark A Canfield (MA)

Birth Defects Epidemiology and Surveillance Branch, Texas Department of State Health Services, Austin, Texas, USA.

Pierpaolo Mastroiacovo (P)

International Center on Birth Defects, International Clearinghouse for Birth Defects Surveillance and Research, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH